Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 161 publications
Preclinical assessment of GNEwt/bi-shRNA-GNEM743T lipoplex product development for GNE myopathy.
Journal: Future science OA
Published: March 02, 2026
Gemogenovatucel-T Advantage in Clonal Tumor Mutation Burden-High Ovarian Cancer.
Journal: JCO precision oncology
Published: January 14, 2026
In Vivo Assessment of dbDNA GNEwt/bi-shRNA-GNEM743T Lipoplex for GNE Myopathy: Improved Potency and Safety.
Journal: The journal of gene medicine
Published: June 25, 2025
Clinical characterization and therapeutic targeting of fusion genes in oncology.
Journal: Future oncology (London, England)
Published: March 24, 2025
Exome sequencing shows same pattern of clonal tumor mutational burden, intratumor heterogenicity and clonal neoantigen between autologous tumor and Vigil product.
Journal: Scientific reports
Published: September 28, 2024
Gemogenovatucel-T (Vigil): bi-shRNA plasmid-based targeted immunotherapy.
Journal: Future oncology (London, England)
Published: August 05, 2024
Regulatory role of CD39 and CD73 in tumor immunity.
Journal: Future oncology (London, England)
Published: April 23, 2024
3D engineered scaffold for large-scale Vigil immunotherapy production.
Journal: Scientific reports
Published: April 04, 2024
Targeted Combination of Poly(ADP-ribose) Polymerase Inhibitors and Immune Checkpoint Inhibitors Lacking Evidence of Benefit: Focus in Ovarian Cancer.
Journal: International journal of molecular sciences
Published: December 12, 2023
Smart exosomes enhance PDAC targeted therapy.
Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: November 02, 2023
Clonal Neoantigen: Emerging "Mechanism-based" Biomarker of Immunotherapy Response.
Journal: Cancers
Published: October 18, 2023
Last Updated: 09/26/2026